Evidence map›Paper›PMID 42407118›Full record

ArticleBriefings in bioinformatics2026

Exploring per-base quality scores as a surrogate marker of cell-free DNA fragmentome.

Hadas Volkov, Maria Raitses-Gurevich, Meitar Grad, Rani Shlayem, Dev Leibowitz, Tami Rubinek, Talia Golan, Noam Shomron

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hadas VolkovGray Faculty of Medical and Health Sciences, Tel Aviv University, P.O. Box 39040, Ramat Aviv, Tel Aviv 6997801, Israel.ORCID 0009-0000-1749-405X
Maria Raitses-GurevichThe Jusidman Cancer Center, Sheba Medical Center, P.O. Box 12, Tel HaShomer, Ramat Gan 52621, Israel.
Meitar GradGray Faculty of Medical and Health Sciences, Tel Aviv University, P.O. Box 39040, Ramat Aviv, Tel Aviv 6997801, Israel.
Rani ShlayemGray Faculty of Medical and Health Sciences, Tel Aviv University, P.O. Box 39040, Ramat Aviv, Tel Aviv 6997801, Israel.
Dev LeibowitzGray Faculty of Medical and Health Sciences, Tel Aviv University, P.O. Box 39040, Ramat Aviv, Tel Aviv 6997801, Israel.
Tami RubinekGray Faculty of Medical and Health Sciences, Tel Aviv University, P.O. Box 39040, Ramat Aviv, Tel Aviv 6997801, Israel.
Talia GolanGray Faculty of Medical and Health Sciences, Tel Aviv University, P.O. Box 39040, Ramat Aviv, Tel Aviv 6997801, Israel.
Noam ShomronGray Faculty of Medical and Health Sciences, Tel Aviv University, P.O. Box 39040, Ramat Aviv, Tel Aviv 6997801, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Per-base quality scores are widely treated as technical metadata in next-generation sequencing. Here, we show that in rigorously controlled whole-genome sequencing of cell-free DNA, quality profiles may carry fragmentomic-associated signal that enables classification of cancer samples against matched controls. Analyzing four independent batches (23 cancer samples: pancreatic and breast; 22 matched controls) sequenced in a within-lane regime and further normalized per flow-cell tile to reduce technical confounders, we demonstrate through unsupervised analysis that boundary-enriched dynamics captured in these quality scores consistently separate cancer from control samples. A leave-one-batch-out classifier trained on quality-derived scores achieved a pooled area under the curve of 0.81. Furthermore, we show that the quality-derived metric correlates with short-fragment enrichment and tumor-associated 5'-end motifs, performing comparably to established, motif-based orthogonal methods. These results provide initial evidence that quality scores could serve as a low-cost, alignment-free surrogate signal for cfDNA-based cancer detection.

Indexed as

Biomarkers, TumorCell-Free Nucleic AcidsHigh-Throughput Nucleotide SequencingHumansBiomarkers, TumorCell-Free Nucleic Acidsbiomarkerscell-free DNAfragmentomicsliquid biopsyNGSquality scores

Identifiers

PMID42407118
PMCPMC13336638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.